Nuclear Medicine Communications最新文献

{"title":"PET for predicting chemoradiotherapy survival in cervical cancer: the search continues.","authors":"Matheus Henrique Leite E Silva, Matheus Aleixo Barbosa da Silva, Daniel Simões Reis Dos Santos, Theara Cendi Fagundes, Angélica Nogueira-Rodrigues, Andreia Cristina de Melo, Andrea Lima Bastos, Marcelo Mamede","doi":"10.1097/MNM.0000000000001999","DOIUrl":"10.1097/MNM.0000000000001999","url":null,"abstract":"<p><strong>Objective: </strong>Cervical c ancer is still a global health concern. The push for personalized care has been the mainstay and the use of noninvasive approaches to stratify patients is a corollary of this management strategy. 18 F-fluorodeoxyglucose PET/computed tomography is frequently used for cervical c ancer staging. Identifying predictive factors PET-based imaging scores could mean increased benefit for these patients, at no increased cost.</p><p><strong>Methods: </strong>An observational study was conducted with stage IIB-IIIB cervical cancer patients receiving erlotinib concomitantly to standard therapy. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, waterfall, and heatmap plots to investigate survival associations. Maximum and average PET measures were obtained before and 3 months after treatment.</p><p><strong>Results: </strong>Thirty patients were enrolled in this phase I/II study. IIB Staging was significantly associated with longer survival when compared with IIIB. Simultaneous lower 2SD algorithm mean standard uptake value (SUV 2SD ) (<4.1) and greater BMI reduction (< -0.17 kg/m 2 ), or lower PERCIST SUV (SUV per ) (<7.6) and greater BMI reduction, predicted worse overall and progression-free survival ( P < 0.05). Unifying pretreatment maximum SUV (SUV max ), SUV per , and SUV 2SD demonstrated a trend toward significant overall survival stratification ( P = 0.057). In the heatmap analysis, there was a lack of high percentile pretreatment tumor-to-liver ratio, SUV max , SUV per , and SUV 2SD features in patients with worse endpoints. The waterfall plots suggested pretreatment lesion volume may predict volume reduction.</p><p><strong>Conclusion: </strong>SUV 2SD and SUV per , paired with BMI variation, were associated with survival prediction. PET might play an important role in individualizing patients before treatment decisions for optimal management of locally advanced disease.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"809-815"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of prostate-specific membrane antigen intraprostatic radiological yield score, prostate-specific membrane antigen expression score, and lesion standardized uptake value and their combination with multiparametric MRI for evaluation of clinically significant prostate cancer: a single-center retrospective study.","authors":"Suraj Kumar, Yamini Mathur, Anjali Meena, Bhagwant Rai Mittal, Harmandeep Singh, Viper Sharma, Stefan Vöö, Rajender Kumar, Santosh Kumar, Ravimohan Mavuduru, Girdhar Bora, Nandita Kakkar, Ujwal Gorsi","doi":"10.1097/MNM.0000000000002008","DOIUrl":"10.1097/MNM.0000000000002008","url":null,"abstract":"<p><strong>Objective: </strong>To compare the prostate-specific membrane antigen intraprostatic radiological yield (PRIMARY)-score, prostate-specific membrane antigen (PSMA)-expression score, and lesion standardized uptake value (SUV)max and their combination with multiparametric MRI (MpMRI) for the detection of clinically significant prostate cancer (csPC).</p><p><strong>Materials and methods: </strong>Our retrospective study analyzed 381 patients with suspicion of prostate cancer who underwent 68 Ga-PSMA PET/computed tomography (CT) between January 2021 and December 2022. Among these, 170 patients also underwent MpMRI. PSMA-PET/CT were interpreted using PRIMARY score, PSMA-expression score, and lesion SUV. Diagnostic performance of PSMA-PET/CT, MpMRI, and their combination was assessed.</p><p><strong>Results: </strong>Among 381 patients, 244 (64.0%) were diagnosed with csPC. PRIMARY-score demonstrated higher sensitivity (96.3%) and negative predictive value (NPV) (85.9%) compared with PSMA-expression score (sensitivity: 89.7%, NPV: 70.6%) and lesion SUV (sensitivity: 90.6%, NPV: 74.2%). Excellent inter-reader agreement ( κ > 0.85) was seen among the readers for both PRIMARY score and PSMA-expression score. In the subset of 170 patients, SUV-based assessment with a cutoff of 8.2 [area under curve (AUC): 0.79] and PRIMARY-score (AUC: 0.77) showed comparable performance to each other and were seen to be superior to MpMRI (AUC: 0.68) ( P  < 0.05). The combination of PRIMARY-score and MpMRI achieved 100% sensitivity and NPV. In Prostate Imaging Reporting and Data System (PIRADS)-positive cases, negative PRIMARY-scores could potentially avoid 13.9% of unnecessary biopsies and positive PRIMARY-scores could detect csPC in an additional 29.3% (12/41) of PIRADS-negative cases.</p><p><strong>Conclusion: </strong>PRIMARY-score showed excellent reproducibility and higher sensitivity and NPV compared with the PSMA-expression score and lesion SUV for detection of csPC. PRIMARY-score also demonstrated an additive benefit for csPC detection when combined with MpMRI while reducing unnecessary biopsies.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"862-871"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and clinical evaluation of cyclotron-produced [ 68 Ga]PSMA-11 and [ 18 F]PSMA-1007 for prostate cancer imaging.","authors":"Muhammad Fakhrurazi Bin Ahmad Fadzil, Mohd Fazrin Bin Mohd Rohani, Muhammad Adib Abdul Onny, Zarif Ashhar, Mohamad Aminudin Bin Said, Mazurin Mahamood, Nik Muhammad Fitri Nik Afinde, Noratikah Mat Ail, Zaitulhusna Md Safee, Nor Idayu Razali, Hamdi Noor, Mohd Firdaus Abdul Aziz, Norsalita Ali, Nurul Ain Yaacob, Radziatul Shahirah Abdul Rahman, Chen Siew Ng, Tharmasilen Selvarajoo","doi":"10.1097/MNM.0000000000002009","DOIUrl":"10.1097/MNM.0000000000002009","url":null,"abstract":"<p><strong>Objective: </strong>To compare the radiochemical synthesis, stability, and clinical performance of cyclotron-produced [ 18 F]PSMA-1007 and [⁶⁸Ga]PSMA-11 for prostate-specific membrane antigen (PSMA)-targeted PET/computed tomography (CT) imaging in prostate cancer.</p><p><strong>Methods: </strong>Six production runs each of [¹⁸F]PSMA-1007 and [⁶⁸Ga]PSMA-11 were conducted using a cyclotron-based system. Radiochemical yield, radiochemical purity, and product stability were evaluated according to European Pharmacopeia standards. Thirty-five patients with prostate cancer underwent dual-tracer PET/CT imaging within 30 days. Images were assessed for lesion detectability, biodistribution, and pitfalls by three independent nuclear medicine physicians using semiquantitative metrics.</p><p><strong>Results: </strong>[¹⁸F]PSMA-1007 demonstrated substantially higher end-of-synthesis activity (mean: 75.68 GBq) compared with [⁶⁸Ga]PSMA-11 (mean: 1.76 GBq), with both achieving high RCP (>98%) and comparable synthesis durations. Stability testing confirmed [¹⁸F]PSMA-1007 remained radiochemically stable for up to 9 h. Clinically, both tracers showed high concordance in PSMA-avid lesion detection. [¹⁸F]PSMA-1007 exhibited superior contrast in prostate and skeletal lesions because of minimal urinary excretion but also revealed higher rates of benign uptake in ganglia and nonspecific bone sites, leading to increased discordant findings (104 vs. 47 lesions).</p><p><strong>Conclusion: </strong>[¹⁸F]PSMA-1007 provides significant advantages in production scalability and lesion detectability, particularly in skeletal and pelvic regions; however, its higher rate of benign uptake necessitates careful interpretation to avoid false positives. While both tracers are clinically effective, tracer selection should be guided by logistical feasibility, clinical context, and interpretive considerations.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"872-883"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study of [ 18 F]fluoro-L-dopa PET/computed tomography imaging to evaluate the extent of liver fibrosis.","authors":"Kai Zhang, Manman Qi, Jingai Jian, Zhi Li, Haiyan Wang, Yue Liu, Jian Zhang","doi":"10.1097/MNM.0000000000002012","DOIUrl":"10.1097/MNM.0000000000002012","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to evaluate the feasibility of using 6-[ 18 F]fluoro-L-dopa ([ 18 F]FDOPA) PET/computed tomography (PET/CT) imaging, targeting dopamine receptor D1 (DRD1), for the noninvasive assessment of liver fibrosis severity.</p><p><strong>Methods: </strong>A rat model of liver fibrosis with different degrees of fibrosis was established. [ 18 F]FDOPA PET/CT imaging was performed to measure the radioactivity uptake in the liver. The stage of liver fibrosis was determined through pathological testing, and the correlation between imaging findings and the fibrosis stage was assessed. In addition, the expression levels of DRD1 and dopa decarboxylase (DDC) were detected to evaluate the relationship between liver uptake and DRD1 expression.</p><p><strong>Results: </strong>The 29 surviving rats were categorized into stages F0-F4 according to the Metavir grading system based on the hematoxylin and eosin and Masson staining pathology findings. Liver radioactivity uptake was significantly and positively correlated with the stage of liver fibrosis ( r  = 0.8006, P  < 0.001). After adjusting for errors using the ratio method, the area under the curve (AUC) for PET/CT imaging to discriminate significant liver fibrosis from no fibrosis and severe liver fibrosis from mild-to-moderate liver fibrosis were 0.9342 and 0.9639, respectively, at the optimal cut-off value. DRD1 expression was significantly correlated with both liver fibrosis stage ( r  = 0.9412, P  < 0.001) and relative uptake value ( r  = 0.8182, P  < 0.001).</p><p><strong>Conclusion: </strong>[ 18 F]FDOPA PET/CT imaging is a valuable tool for assessing liver fibrosis severity. The level of radioactivity uptake in the liver is significantly correlated with the degree of liver fibrosis and DRD1 expression level.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"884-894"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between brown adipose tissue activity, serum lipid profiles, and cardiovascular events: insights from 18 F-fluorodeoxyglucose PET/computed tomography analysis.","authors":"Kewei Yang, Ruiqiu Zhang, Xiaohui Zhang, Qiaoling Gao, Xiuyu Guo, Lianyu Gu, Han Zhang, Jingfeng Zhang, Jianjun Zheng, Maoqing Jiang","doi":"10.1097/MNM.0000000000002007","DOIUrl":"10.1097/MNM.0000000000002007","url":null,"abstract":"<p><strong>Objective: </strong>This study investigated the associations between brown adipose tissue (BAT) metabolic parameters, serum lipid profiles, and cardiovascular disease (CVD) events.</p><p><strong>Methods: </strong>A retrospective cohort study involving 13 530 patients who underwent 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography between November 2019 and March 2024 was conducted to evaluate semiquantitative BAT indices, including the maximum standardized uptake value (B-SUV max ), total metabolic volume (TBMV), and total BAT glycolytic activity (TBG), as well as their associations to lipid profiles [total cholesterol (TC), triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TC/HDL-C and LDL-C/HDL-C ratios) and CVD outcomes. Propensity score matching was applied, resulting in a comparison group of 74 BAT-positive patients and 148 BAT-negative controls.</p><p><strong>Results: </strong>BAT-positive individuals exhibited significantly higher HDL-C levels ( P  = 0.005) and lower TC/HDL-C ( P  = 0.006) and LDL-C/HDL-C ( P  = 0.014) ratios compared with controls, while no significant differences were observed in triglyceride, TC, or LDL-C levels. TBG showed the strongest correlations with HDL-C ( r  = 0.256, P  < 0.001), TC/HDL-C ( r = -0.223, P  < 0.001), and LDL-C/HDL-C ( r = -0.195, P  = 0.004), outperforming B-SUV max and TBMV. Patients exhibiting BAT had a lower incidence of CVD events compared to those without detectable BAT ( P  = 0.018). Multivariate logistic regression analysis showed that the presence of BAT is an independent predictor of CVD events.</p><p><strong>Conclusion: </strong>TBG is a moderate biomarker reflecting HDL-C levels and the ratios of TC/HDL-C and LDL-C/HDL-C, while detectable BAT activity independently correlates with reduced CVD risk, highlighting its potential for cardiovascular risk stratification.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"855-861"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144310271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the Prostate Imaging for Recurrence Reporting (PI-RR) System using 68 Ga prostate-specific membrane antigen-11 (HBED-CC) PET/MRI in biochemical recurrence of prostate cancer: a pilot study.","authors":"Lebriz Uslu-Beşli, Baris Turkbey, Bariş Bakir, Selahattin Durmaz, Çetin Demirdağ, Haluk Burçak Sayman","doi":"10.1097/MNM.0000000000002016","DOIUrl":"10.1097/MNM.0000000000002016","url":null,"abstract":"<p><strong>Objective: </strong>To assess the diagnostic performance of Prostate Imaging for Recurrence Reporting (PI-RR) system using 68 Ga prostate-specific membrane antigen (PSMA)-11 (HBED-CC) PET/MRI in prostate cancer (PCa) patients with biochemical recurrence (BCR).</p><p><strong>Methods: </strong>PET/MRI data of 31 PCa patients [17 with radical prostatectomy (RP) and 14 with radiotherapy (RT)] with BCR were retrospectively analyzed. All patients underwent PSMA PET/MRI and multiparametric prostate MRI (mpMRI). Images were evaluated using PI-RR system for mpMRI and the European Association of Nuclear Medicine standardized reporting guidelines (E-PSMA) for PET, with PI-RR and E-PSMA scores dichotomized as ≤2 negative and ≥3 positive for recurrence. Diagnostic performances were assessed using expert-based ground truth establishment.</p><p><strong>Results: </strong>Sensitivity, specificity, and accuracy were 64.7%, 85.7%, and 74.2%, respectively, for PET and 70.6%, 100%, and 83.9%, respectively, for PI-RR. While PI-RR did not reveal any false positive lesions, five patients with false negative PI-RR results were also negative with PET. In patients with RP, sensitivity, specificity, and accuracy were 44.4%, 100%, and 70.6%, respectively, for PET and 55.6%, 100%, and 76.5%, respectively, for PI-RR. For patients with RT, these values were 87.5%, 66.7%, and 78.6%, respectively, for PET and 87.5%, 100%, and 92.9%, respectively, for PI-RR. There was no significant performance difference between PET or PI-RR in all patients ( P = 0.564), patients with RP ( P = 0.317), or RT ( P = 0.157).</p><p><strong>Conclusion: </strong>68 Ga PSMA PET evaluation with E-PSMA and mpMRI interpretation with PI-RR have similar diagnostic performance for detection of local recurrence after RP or RT in PCa.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"895-904"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of 18 F-FDG PET on management in patients with recurrent head and neck cancer: a meta-analysis.","authors":"Hai-Jeon Yoon, Kyoungjune Pak","doi":"10.1097/MNM.0000000000002005","DOIUrl":"10.1097/MNM.0000000000002005","url":null,"abstract":"<p><strong>Objective: </strong>Head and neck cancers (HNC) comprise malignancies occurring in the oral cavity, pharynx, larynx, and salivary glands. This meta-analysis assessed the effect of 18 F-fluorodeoxyglucose (FDG) PET on the management of recurrent HNC.</p><p><strong>Methods: </strong>We conducted systematic reviews focused on the role of FDG PET in managing recurrent HNC. We defined management change as the percentage of patients whose treatment was altered following FDG PET results relative to those assessed with this imaging technique.</p><p><strong>Results: </strong>We included seven studies encompassing 444 patients. The studies evaluated the role of FDG PET in detecting recurrence or metastasis in HNC patients by examining the rates of management change, with a pooled effect of 26.6%.</p><p><strong>Conclusion: </strong>The findings from our meta-analysis indicate that FDG PET substantially affects the management of patients with recurrent HNC. These outcomes align with current guidelines recommending the use of FDG PET under these circumstances.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"848-854"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the diagnostic and prognostic impact of posttreatment fluorine-18 fluorodeoxyglucose PET/computed tomography on M0 esophageal cancer.","authors":"Chang-Shen Tseng, Bee-Song Chang, Shu-Hang Ng, Shu-Hsin Liu, Jason Chia-Hsun Hsieh, Sheng-Chieh Chan","doi":"10.1097/MNM.0000000000002004","DOIUrl":"10.1097/MNM.0000000000002004","url":null,"abstract":"<p><strong>Objective: </strong>Fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) is an essential examination to stage patients with esophageal cancer; however, the role of posttreatment [18F]FDG PET/CT in patients with esophageal cancer has not been well explored. We aimed to investigate the prognostic and diagnostic value of posttreatment PET/CT in patients with esophageal cancer after their definitive treatment.</p><p><strong>Methods: </strong>This retrospective study enrolled 208 patients with biopsy-proven esophageal cancer. Posttreatment PET/CT scans were performed greater than or equal to 3 months after the completion of definitive therapy, with a total of 539 scans included in this study. The outcome measures were the diagnostic capacity of PET/CT and patient survival. Survival analysis was conducted using Kaplan-Meier plots, accompanied by the Mantel-Cox log-rank test and Cox regression.</p><p><strong>Results: </strong>The sensitivity, specificity, and accuracy of posttreatment PET/CT for recurrent tumors were 93.67, 92.65, and 92.95%, respectively. PET/CT identified recurrent tumors in 24.58% of scans obtained for tumor surveillance and ruled out recurrence in 40.30% of scans obtained with prior clinical suspicion. Negative PET/CT had a predictive value of 80% for nonrecurrence before the next planned scan, while positive PET results were significantly associated with poorer patient survival following the scan ( P < 0.0001). In the multivariate Cox regression model, the PET/CT result was identified as an independent prognostic factor [ P < 0.0001, hazard ratio (HR)=3.818] with a higher hazard ratio compared with the tumor stage ( P = 0.01, HR=1.633) or treatment modality ( P = 0.0002, HR = 2.035).</p><p><strong>Conclusion: </strong>We illustrate the favorable performance of posttreatment [18F]FDG PET/CT in both detecting tumor recurrence and evaluating the prognosis of patients with M0 esophageal cancer. These findings imply the potential of [18F]FDG PET/CT as a follow-up imaging modality in these patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"816-823"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volumetric 68 Ga- prostate-specific membrane antigen PET/computed tomography analysis of bone metastasis subtypes in prostate cancer: correlation with prostate-specific antigen and International Society of Urological Pathology grade.","authors":"Nihat Koyluce, Ummuhan Abdulrezzak, Ahmet Tutus","doi":"10.1097/MNM.0000000000002044","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002044","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to determine the rate of metastasis types in prostate cancer (PCa) patients with bone metastasis and to evaluate the relationship between volumetric parameters obtained from gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) and prostate-specific antigen (PSA) levels.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed the images of patients who underwent 68Ga PSMA PET/CT for restaging for recurrent PCa between 2014 and 2019. All detected bone lesions were manually grouped as 'osteoblastic (OB), osteolytic (OL), mixed (M), and radio-occult (RO) lesions' and the number and percentage were determined. Different volumetric values are obtained for each type of bone metastasis using the LIFEx v7.3.0 program. The relationship between PSA level and these volumetric values will be determined by the Spearman correlation test. The relationship between the International Society of Urological Pathology (ISUP) PCa grade group and volumetric values will be evaluated by the Kruskal-Wallis correlation test.</p><p><strong>Results: </strong>Seventy-one patients had a total of 599 bone metastasis. Of these lesions, 268 were OB (44.7%), 39 were OL (6.5%), 72 were M (12.0%), and 220 were RO (36.7%). Total lesion volume (TLV) (p: 0.001), total lesion activity (TLA) (p: 0.001), and OB-TLA (p: 0.042) were significantly different between ISUP grades. In addition, the total number of lesions showed a statistically significant difference between ISUP grades (p: 0.019). PSA level correlated with RO lesion number (r: 0.404, p: 0.016), RO-TLV (r: 0.471, p: 0.004), and RO-TLA (r: 0.528, p: 0.001).</p><p><strong>Conclusion: </strong>68Ga-PSMA PET/CT can identify the source of biochemical recurrence by detecting RO lesions at early stages when bone mineral density is not affected.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfer learning can predict the presence of hibernating myocardium from rest myocardial perfusion images.","authors":"Bangkim Chandra Khangembam, Jasim Jaleel, Arup Roy, Ritwik Wakankar, Priyanka Gupta, Chetan Patel","doi":"10.1097/MNM.0000000000002043","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002043","url":null,"abstract":"<p><strong>Purpose: </strong>Hibernating myocardium is a viable but dysfunctional myocardium state caused by chronic ischemia, with potential for recovery postrevascularization. This study evaluates the feasibility of transfer learning for predicting hibernating myocardium from rest myocardial perfusion images.</p><p><strong>Methods: </strong>Patients who underwent myocardial viability assessment from January 2017 to September 2022 were split into training (70%) and validation (30%) sets, while those from October 2022 to January 2023 formed the testing set. Hibernating myocardium was defined as a mismatched perfusion-metabolism defect with impaired contractility. Rest myocardial perfusion polar maps were embedded using Google's InceptionV3, followed by data normalization and analysis of variance-based feature selection. Three gradient boosting algorithms were trained with stratified 10-fold cross-validation, validated, and tested. Performance was assessed using area under the curve (AUC), classification accuracy (CA), F1 score, specificity, and model interpretability via SHapley Additive exPlanations (SHAP) plots.</p><p><strong>Results: </strong>The study included 239 patients (214 males, 25 females, mean age 56 ± 11 years); 123 (51.5%) had hibernating myocardium. All models achieved >0.700 in performance metrics across all datasets. Among them, extreme gradient boosting (xgboost) performed best on the test set (F1 score: 0.800, CA: 0.774, specificity: 0.909, AUC: 0.782). Beeswarm SHAP plots revealed a clear pattern of model interpretability for all models.</p><p><strong>Conclusion: </strong>This study demonstrates the feasibility of transfer learning for predicting hibernating myocardium from rest myocardial perfusion images. The integration of deep convolutional neural networks with gradient boosting models highlights the potential of machine learning-based myocardial viability assessment, contributing valuable early evidence.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}